Skip Navigation
Center for Mind Body Research
CMBR

CMBR Home

Faculty

Research

Courses & Seminars

Events Calendar

Visting Scholars

Resources

Funding Opportunities
- CMBR
- Other

Mentoring Program
- For Mentees
- For Mentors

Members Only

Related Links

 
NEWS & EVENTS

Michelle Petri
Professor

Academic Degrees
M.D., Harvard Medical School, 1980

Departmental Affiliation
Dept of Med - Rheumatology

Departmental Address
1830 Building, Suite 7500
600 North Wolfe Street
Baltimore, MD 21205

Email: mpetri@jhmi.edu
Phone: (410) 955-9114
Fax: (410) 614-0498

Honors and Awards:

Merit Scholar, Phi Beta Kappa

1988 - 1991       Clinical Associate Physician Award (NIH)
1991 - 1993       Hopkins Clinician Scientist
1993                 Dubois Award, American College of Rheumatology

Committees:

1992-Present

Lupus Foundation of America, Education Committee

1993-Present

American College of Rheumatology, Council on Research, Sub-committee for Clinical Trials

1993-Present

American College of Rheumatology, Sub-committee for Medical Student Recruitment

1994-Present

FDA Arthritis Advisory Committee; chairman 1997 to 1998

Selected Publications

Petri M., Rheinschmidt M., Whiting-O'Keefe Q., Hellmann D., Corash L. (1987). The Frequency of Lupus Anticoagul-ant in Systemic Lupus Erythematosus: A Study of 60 Consecutive Patients by Activated Partial Thrombo-plastin Time, Russell Viper Venom Time, and Anticardiolipin Antibody. Ann Int Med, 106, 524-531.

Petri M., Golbus M., Anderson R., Whiting-O'Keefe Q., Corash L., and Hellmann D.  Antinuclear Antibodies, Lupus Anticoagulant, and Anticardiolipin Antibody in Idiopathic Habitual Abortion: A Controlled Prospective

Petri M., Spence D., Bone L.R., Hochberg M.C. (1992). Coronary artery disease risk factors in the Hopkins Lupus Cohort:  prevalence, patient recognition, and preventive practices.  Medicine, 71, 291-302.

Petri M, Perez-Gutthann S, Spence D, Hochberg MC. (1992). Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med, 93, 513-519.

Petri M. (1995). Musculoskeletal Complications of Systemic Lupus Erythematosus in the Hopkins Lupus Cohort:  An Update. Arthritis Care and Research, 8,137-145.

Petri M., Roubenoff R., Nadeau M.R., Selhub J., Rosenberg I.H. (1996). Plasma homocysteine is a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet, 348, 1120-1124.

Petri M. (1996). Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. Lupus, 5 (Suppl. 1), S16-S22.

Mont M.A., Glueck C.J., Pacheco I., Wang P., Hungerford D.S., Petri M. (1997). Risk factors for osteonecrosis in systemic lupus erythematosus. J Rheumatol, 24, 654-662.

Gladman D., Urowitz, M.B., Goldsmith C.H., Fortin P., Ginzler E., Gordon C., Hanly J., Isenberg D., Kalunian K., Nived O., Petri M., Sanchez-Guerrero J., Snaith M., Sturfelt G. (1997). Reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum, 40, 809-813.

Sasso E.H., Suzuki L.A., Thompson A.R., Petri M.A. (1997). Hereditary resistance to activated protein C: an uncommon risk factor for thromboembolic disease in lupus patients with antiphospholipid antibodies. Arthritis Rheum, 40, 1720-1721.

Mont M.A., Fairbank A.C., Petri M., Hungerford D.S. (1997). Core decompression for osteonecrosis of the femoral head in systemic lupus erythematosus. Clin Orthop Jan (334), 91-97.

Sullivan K.E., Wooten C., Schmeckpeper B.J., Goldman D., Petri M.A. (1997). A promotor polymorphism of tumor necrosis factor associated with systemic lupus erythematosus in African Americans. Arthritis Rheum, 40, 2207-2211.

Mathis J.M., Petri M., Naff N. (1998). Percutaneous vertebroplasty treatment of steroid induced osteoporotic compression fractures. Arthritis Rheum, 41, 171-175.

Petri M. (1998). Hopkins Lupus Cohort:  The effect of race on incidence and clinical course in systemic lupus erythematosus: the Hopkins Lupus Cohort. J Am Med Women’s Assoc, 53, 9-12

Brodsky R.A., Petri M., Smith B.D., Seifter E.J., Spivak J.L., Styler M., Dang C.V., Brodsky I., Jones R.J. (1998). Immunoblative high-dose cyclophosphamide without stem cell rescue for refractory, severe autoimmune disease. Ann Int Med, 129, 1031-1035.

American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines. Guidelines for Referral and Management of Systemic Lupus Erythematosus in Adults. Arthritis and Rheum, 42, 1785-1796, 1999.

 Barr S., Zonana-Nacach A., Magder L., Petri M. (1999). Patterns of disease activity in systemic lupus erythematosus. Arthritis Rheum, 42, 2682-2688.

Gladman D.D., Goldsmith C.H., Urowitz M.B., Bacon P., Fortin P., Ginzler E., Gordon C., Hanly J.G., Isenberg D.A., Petri M., Nived O., Snaith M., Sturfelt G., for the Systemic Lupus International Collaborating Clinics. (2000). The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison. J Rheumatol, 27, 373-376.

Akkasilpa S., Minor M., Goldman D., Magder L.S., Petri M. (2000). Association of coping responses with fibromyalgia tender points in patients with SLE. J Rheumatol, 27, 671-674.

Strand V (for the OMERAC SLE Steering Committee), Gladman D., Isenberg D., Petri M., Smolen J., Tugwell P. (2000). Endpoints: consensus recommendations from OMERACT IV. Lupus, 9, 322-327.

Zonana-Nacach A., Barr S.G., Magder L.S., Petri M. (2000). Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum, in press,

Petri M. (2000). Epidemiology of the anti-phospholipid antidody syndrome. J Autoimmunity, 15, 145-151.

Segal J., Kickler T., Petri M. (2000). Tissue Factor activity inpatients with SLE: association with disease activity. J Rheumatol, 27, 2827-2832.

Leritz E., Brandt J., Reis-Jenson F., Petri M. (2000). “Subcortical” cognitive impairment in patients with systemic lupus erythematosus. J Int Neuropsychological Soc, 6, 821-825.

Petri M. (2000). The egg and I: preserving fertility in systemic lupus erytheamtosus. Lupus, 9, 399-400.

Petri, M. Infertility, Oral Contraceotive Pills, Hormone Replacement Therapy and Antiphospholipid Syndrome. Ina; Khamashta, MA edd. Hughes Syndrome Antiphospholipid Syndrome. Springer-Verlag, London, pp 426-446,2000.

Petri, M. (2000). Systemic Lupus Erythematosus: Clinical aspects. In: Koopman, WJ ed. Arthritis and Allied Conditions. Lippincott Williams 26:377-388.

Petri M. (2000). Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort. 9:170.

Petri M. (2000). Approach to the Management of Systemic Lupus Erythematosus. J. Clin. Outcomes Management, 7(8), 56-61.

Petri M., & Buyon J. (2001). SELENA: Safety of Estrogens of Lupus Erythematosus: National Assessment. Lupus News, 21(3), 20.

Ines L.S., Petri M. (2001). Mycophenolate Mofetil: an emerging therapeutic option for systemic lupus erythematosus. Acta Reumatologica Portuguesa, 26, 153-162.

Petri, M Treatment of Antiphospholipid Antibody Syndrome: Has There Been Any Progress in the Last Five Years? Curr Rheumatol Reports, in press, 2001. Petri, M, Provost TT. Antiphospholipid Syndrome. In: Provost, TT, and Flynn, JA eds. Cutaneous Medicine: Cutaneous Manifestations of Systemic Disease. BC Decker Inc., Hamilton, Canada, pp. 147-157, 2001.

Petri, M. Homocystein and vascular disease in autoimmune connective tissue disease. In: Cervera R, Asherson R eds. Vascular Manifestations of Systemic Autoimmune Disease. CRC Press, New York, 2001 pp. 71-80.

Casciola-Rosen LA, Pluta AF, Poltz PH, Cox AE, Morris S, Wigley FM, Petri M, Gelber AC, Rosen A. The DNA mismatch repair enzyme PMS1 is a myositis-specific autoantigen. Arthritis Rheum 44:389-396,2001.

Petri, M . Exogenous estrogen in systemic lupus erythematosus: oral contraceptives and hormone replacement therapy. Lupus 10:222-226, 2001.

Verthelyi D, Petri M, Ylamus M, Klinman DM. Disassociation of sex hormone levels and cytokine production in SLE patients. Lupus 10:352-358,2001.

Ho A, Barr SG, Magder LS, Petri M. A decrease in complement is associated with increased renal and hematologic flares in patients with systemic lupus erythematosus. Arthritis and Rheum 44:2350-2357,2001.

Ho A, Magder LS, Barr SG, Petri M. Decrease in anti-double stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis and Rheum 44:2342-2349,2001.

Asherson RA, Cervera R, Piette J-C, Shoenfeld Y, Espinosa G, Petri MA, Lim E, Lau C, Gurjal A, Jedryka-Goral A, Chwalinska-Sadowska H, Dibner RJ, Rojas-Rodriguez J, Garcia-Carrasco M, Grandone JT, Parke AL, Barbosa P, Vasconcelos C, Ramos-Casa M, Font J, Ingelmo M. Catatrophic antiphospholipid syndrome: clues to the pathogenisis from a series of 80 patients. Medicine 80:355-377,2001.

Alarcon GS, McGwin Jr G, Petri M, Reveille JD, Ramesey-Goldman R, Kimberly RP. Baseline characteristics of a multicenter lupus cohort: profile. Lupus, in press, 2001.

Petri MA, Lahita RG, van Vollenhoven RF, Merrill JT, Schiff M, Ginzler EM, Strand V, Kunz A, Gorelick KJ, Schwartz KE for the GL701 Lupus Group. Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus. Arthritis Rheum, in press, 2001.

Petri, M. Systemic lupus erythematosus (Including Pregnancy and Antiphospholipid Antibody Syndrome). In: Weisman M, Weinblat M eds. Drug Therapy for the Rheumatic Diseases, 2nd ed

TOOLS

Join the CMBR
Volunteer for a Study
Contact Us
Email this Page  

Subscribe to Newsletter
Locate an Expert
 

Johns Hopkins MedicineJohns Hopkins Bloomberg School of Public HealthJohns Hopkins University School of Nursing
 

©2016, Johns Hopkins University. All rights reserved.
Web policies, 615 N. Wolfe Street, Baltimore, MD 21205